Cite

HARVARD Citation

    Lee, P. et al. (2020). Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. Journal for immunotherapy of cancer. 8 (2), p. . [Online]. 
  
Back to record